











































































































































Kay, NE, Hamblin, TJ, Jelinek, DF, et al. Chronic Lymphocytic Leukemia. *Hematology* 2002;1:193-213.

Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. *Cancer*. 2002;94:2033-2039.

Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor; dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin binding proteins. *J Biol Chem*. 2008;283(27):18545-52.

Rai KR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *NEJM* 2000;343:1750-7.

Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. *Leuk Lymphoma*. 2007;48:1931-1939.

Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. *Blood*. 2004;104:1793-800.

van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. *Br J Haematol*. 2001 Dec;115(4):807-11

Wierda WW, O'Brien SO, Wen SW, Faderl SF, Garcia-Monero GG, Thomas DT et al. Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. *J Clin Oncol*. 2005; 23: 4070.

Medicinal product no longer authorised